SURF NASDAQ
Cambridge, MA 02139
US
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sigal Charles Elliot | D-Return | 113,636 | $0.35 | 2023-09-08 |
| Sigal Charles Elliot | D-Return | 45,453 | — | 2023-09-08 |
| Adams Chandra | D-Return | 50,000 | $0.69 | 2023-09-08 |
| Adams Chandra | D-Return | 23,884 | — | 2023-09-08 |
| RATH HENRY C. | D-Return | 44,971 | — | 2023-09-08 |